PANoptosis signatures of HCC and the design of PANoptosis inducing drugs for individualized HCC therapy. (IMAGE)
Caption
PANoptosis signatures of HCC and the design of PANoptosis inducing drugs for individualized HCC therapy. Various approaches such as single cell sequencing, proteomics analysis, screening of differentially expressed genes and differential lncRNAs have been used to analyze HCC samples and construct PANoptosis signatures of HCC. From HCC PANoptosis signatures, prognostic markers can be identified to classify patients with HCC into groups and predict their responses to chemotherapy and immunotherapy. Furthermore, therapeutic targets including mRNAs, proteins, and lncRNAs can be identified to design nanoparticles such as Bi2Sn2O7. These specially designed drugs could activate the PANoptosome and induce PANoptosis, thus achieving individualized HCC therapy. HCC, hepatocellular carcinoma.
Credit
Cancer Biology & Medicine
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC